Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

17:07
10/05/16
10/05
17:07
10/05/16
17:07

Alnylam down 42% after drug development halt, Medicines Co. down 3.6%

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.

TODAY'S FREE FLY STORIES

AKTX

Akari Therapeutics

$20.50

4.13 (25.23%)

07:16
04/24/17
04/24
07:16
04/24/17
07:16
Hot Stocks
Akari: Interim Phase 2 PNH data demonstrate 'positive' response with Coversin »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

WGO

Winnebago

$26.25

0.15 (0.57%)

07:15
04/24/17
04/24
07:15
04/24/17
07:15
Initiation
Winnebago initiated  »

Winnebago initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$104.89

0.01 (0.01%)

07:14
04/24/17
04/24
07:14
04/24/17
07:14
Periodicals
Chevron to sell Bangladesh gas fields to Himalaya Energy, Reuters says »

Chevron has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

QTS

QTS Realty Trust

$52.90

-0.14 (-0.26%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Recommendations
QTS Realty Trust analyst commentary  »

QTS Realty Trust named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Hot Stocks
Cara Therapeutics announces 'positive' data from Phase 1 trial of CR845 »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Steel Dynamics rating change  »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.72

-0.1 (-1.47%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
AK Steel rating change  »

AK Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

NUE

Nucor

$60.00

-0.35 (-0.58%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Nucor rating change  »

Nucor upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$30.42

-0.09 (-0.29%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
U.S. Steel rating change  »

U.S. Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
Breaking Hot Stocks news story on AkzoNobel, PPG »

AkzoNobel confirms third…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

SAGE Therapeutics

$72.82

1.19 (1.66%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
SAGE Therapeutics appoints Michael Cloonan as Chief Business Officer »

Sage Therapeutics (SAGE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOMA

XOMA

$7.73

0.26 (3.48%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
XOMA says X213 shown to be safe and effective in phase 2 study »

XOMA Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

AMDA

Amedica

$0.38

0.01 (2.70%)

07:08
04/24/17
04/24
07:08
04/24/17
07:08
Hot Stocks
Amedica announces regulatory clearance to market, sell Valeo in Australia »

Amedica Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.94

-0.09 (-0.22%)

, JPM

JPMorgan

$84.52

-1.03 (-1.20%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Periodicals
HSBC selected to advise on $100B Aramco IPO, Reuters reports »

HSBC (HSBC) has been…

HSBC

HSBC

$39.94

-0.09 (-0.22%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 19

    May

  • 22

    May

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

AKER

Akers Biosciences

$1.80

0.1 (5.88%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
Akers Biosciences says digital apps approved by Apple Store »

Akers Biosciences …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHT

DHT Holdings

$4.60

-0.05 (-1.08%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
DHT Holdings announces delivery of two VLCCs from BW Group »

DHT Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFR

Colony Starwood Homes

$34.82

0.12 (0.35%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Initiation
Colony Starwood Homes initiated  »

Colony Starwood Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
AkzoNobel says will 'carefully review' PPG's third unsolicited proposal »

Akzo Nobel N.V. (AKZOY)…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.26

-0.04 (-0.39%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Initiation
Playa Hotels & Resorts initiated  »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

FLR

Fluor

$50.58

0.09 (0.18%)

, BP

BP

$34.00

-0.15 (-0.44%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
Fluor awarded offshore compression platform FEED by BP »

Fluor (FLR) announced…

FLR

Fluor

$50.58

0.09 (0.18%)

BP

BP

$34.00

-0.15 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:05
04/24/17
04/24
07:05
04/24/17
07:05
Hot Stocks
Paratek, Zai Lab announce collaboration for Omadacycline in China »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTK

Paratek Pharmaceuticals

$22.00

0.4 (1.85%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Paratek highlights potential for omadacycline to provide cost savings vs. SOC »

Paratek Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWLD

Buffalo Wild Wings

$161.75

-2 (-1.22%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Hot Stocks
Buffalo Wild Wings announces filing of proxy materials »

Buffalo Wild Wings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

GWW

Grainger

$195.15

-0.81 (-0.41%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Downgrade
Grainger rating change  »

Grainger downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 19

    Jul

  • 17

    Oct

  • 24

    Jan

ATEC

Alphatec

, CAE

CAE

$15.21

-0.06 (-0.39%)

07:04
04/24/17
04/24
07:04
04/24/17
07:04
Conference/Events
American Association of Neurological Surgeons to hold annual meeting »

2017 AANS Annual…

ATEC

Alphatec

CAE

CAE

$15.21

-0.06 (-0.39%)

EDGE

Edge Therapeutics

$9.02

-0.02 (-0.22%)

MDT

Medtronic

$80.48

-0.54 (-0.67%)

NUVA

NuVasive

$75.02

-0.68 (-0.90%)

SYK

Stryker

$132.94

0.18 (0.14%)

VRTX

Vertex

$116.70

-0.56 (-0.48%)

SYNA

Synaptics

$50.76

-0.34 (-0.67%)

NVIV

InVivo Therapeutics

$3.90

-0.35 (-8.24%)

LMAT

LeMaitre

$25.14

-0.23 (-0.91%)

MZOR

Mazor Robotics

$35.68

0.64 (1.83%)

OFIX

Orthofix

$38.95

0.33 (0.85%)

SSNLF

Samsung

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

SNE

Sony

$33.68

0.85 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 18

    May

  • 24

    May

  • 25

    May

  • 06

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.